Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Zoetis    ZTS

ZOETIS (ZTS)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
01/11/2018 01/12/2018 01/16/2018 01/17/2018 01/18/2018 Date
74.59(c) 75.39(c) 75.54(c) 76.77(c) 76.33(c) Last
1 629 279 1 915 669 2 599 094 2 769 587 2 588 995 Volume
+0.92% +1.07% +0.20% +1.63% -0.57% Change
More quotes
Financials ($)
Sales 2017 5 249 M
EBIT 2017 1 762 M
Net income 2017 1 034 M
Debt 2017 3 706 M
Yield 2017 0,55%
Sales 2018 5 612 M
EBIT 2018 2 033 M
Net income 2018 1 383 M
Debt 2018 3 221 M
Yield 2018 0,63%
P/E ratio 2017 36,76
P/E ratio 2018 27,31
EV / Sales2017 7,79x
EV / Sales2018 7,20x
Capitalization 37 195 M
More Financials
Company
Zoetis, Inc. discovers, develops and manufactures a portfolio of animal health medicines and vaccines, complemented by diagnostic products, genetic tests, bio devices and services, which are designed to meet the needs of veterinarians and the livestock farmers and companion animal.The company was... 
Sector
Pharmaceuticals
Calendar
02/15 | 01:00pmEarnings Release
More about the company
Surperformance© ratings of Zoetis
Trading Rating : Investor Rating :
More Ratings
Latest news on ZOETIS
01/11 ZOETIS : Outlines Path for Future Growth and Value Creation at J.P. Morgan Healt..
01/08 ZOETIS : Therapy Dogs Help in Battle Against Childhood Cancer
01/08 ZOETIS INC. : Regulation FD Disclosure (form 8-K)
2017 ZOETIS : to Host Webcast and Conference Call on Fourth Quarter and Full Year 201..
2017 ZOETIS : to Participate in the 36th Annual J.P. Morgan Healthcare Conference
2017 ZOETIS : Declares First Quarter 2018 Dividend; Board Approves 20% Payment Increa..
2017 ZOETIS INC (NYSE : ZTS) : The Technical Indicator That Works
2017 ZOETIS : to Participate in the 36th Annual J.P. Morgan Healthcare Conference
2017 ZOETIS : Launches Vanguard® CIV H3N2/H3N8 Vaccine for Canine Influenza Virus
2017 ZOETIS INC. : Regulation FD Disclosure (form 8-K)
More news
Sector news : Veterinary Drugs
01:20a At AstraZeneca, fewer drug projects bring big productivity jump
01/18 European shares edge higher as cyclicals back in favour
01/18 ABLYNX : Largest Ablynx investor would consider improved Novo Nordisk bid
01/18 BTG : U.S. court invalidates Johnson & Johnson cancer drug patent, hitting UK's ..
01/17 TSX ends up as banks lead rally after rate hike
More sector news : Veterinary Drugs
Latest Tweets
01/18Jefferies Group Lowers Zoetis FY2017 Earnings Estimates to $2.38 EPS (Previou.. 
01/17Jefferies Group Raises Zoetis FY2018 Earnings Estimates to $3.11 EPS (Previou.. 
01/17Recent Investment Analysts’ Ratings Changes for Zoetis $ZTS  
01/17$AMZN $ADBE $NKE $FB $GOOG $GOOGL $CELG $REGN $PCLN $ORLY $ZTS $TJX $MSFT $AL.. 
01/17Zoetis Inc $ZTS is AMI Asset Management Corp’s 4th Largest Position  
More tweets
Qtime:84
News from SeekingAlpha
01/17 POLEN CAPITAL : Portfolio Manager Commentary Q4 2017
01/13 YOUR DAILY PHARMA SCOOP : Lipocine's Gloomy Future, Puma Labeling Change, Concer..
01/11 7 Upcoming Dividend Hikes
01/11 Zoetis (ZTS) Presents At 36th Annual J.P. Morgan Healthcare Conference - Slid..
01/11 YOUR DAILY PHARMA SCOOP : Roche Highlights Pipeline, GenSight Gets Nod To Start ..
Chart ZOETIS
Duration : Period :
Zoetis Technical Analysis Chart | ZTS | US98978V1035 | 4-Traders
Technical analysis trends ZOETIS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 79,8 $
Spread / Average Target 4,5%
EPS Revisions
Managers
NameTitle
Juan Ramón Alaix President, Chief Executive Officer & Director
Mike B. McCallister Non-Executive Chairman
Kristin C. Peck Executive Vice President & President-US Operations
Glenn David Chief Financial Officer & Executive Vice President
Catherine Ann Knupp Executive VP, President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ZOETIS4.86%37 195
JINYU BIO-TECHNOLOGY CO LTD49.34%4 404
DECHRA PHARMACEUTICALS PLC-4.82%2 555
PHIBRO ANIMAL HEALTH CORP5.52%1 421
VIRBAC-0.89%1 253
PULIKE BIOLOGICAL ENGINEERING INC0.54%1 121